What is Clinical Research Optimized™?
Biorasi is not just a contract research organization. We are a new kind of CRO, dedicated to delivering Clinical Research Optimized™ for our sponsors. We believe that the contract research organization industry is failing sponsors, and we strive achieve the ideal balance of cost, time and risk for our sponsors in every trial . Through innovative processes and technologies, dedication to sponsors, and a culture of ownership, our team will deliver your trial on time and on budget, every time.
KEEP YOUR CLINICAL TRIALS ON TARGET
Biorasi is recognized as a leading expert in delivering success where other CROs fail.
We are a trial rescue expert, recognized for our ability to complete trials that much larger CROs falter on. In our 15 years of experience, we’ve been able to rescue clinical trials from some of the leading names in pharma, lead by some of the most prominent contract research organizations in the world. Our rescue expertise doesn’t just save our sponsors time and money – it saves entire drug development programs.
"One of the rarest events, where we had to communicate [to Biorasi] to stop the screening rather than boost it."VP of Global Clinical Development, Top Specialty Pharma
Clinical trials in neurological diseases often mirror the complexity of the disease itself. Hence, a team tackling this type of clinical trial should make a number of assumptions, some of which are ubiquitous among other therapeutic areas while others are unique for...read more
Innovative and out of the box methods are often required for the recruitment of challenging populations in clinical trials that would otherwise fail miserably when using conventional recruitment strategies. In this arena, Biorasi has positioned itself as a pioneer and...read more
Many of us typically think of Alzheimer’s Disease (AD) when we hear the word “dementia”. This is a fair assumption since AD is indeed the most common type of dementia, and accounts for up to 80 percent of all cases. Because of its prevalence, the AD drug market is...read more
As a Master of Health Administration (MHA) candidate at the University of Miami and a Program Development intern at Biorasi for the last four months, I had the unique opportunity to take a dive into the exciting process of drug development while exploring the...read more
Risk-based monitoring (RBM) is heralded as the new solution to all troubles in clinical research – the exorbitant complexity, the ridiculous costs, the nerve-wracking SAEs. Sponsors and CROs are gradually adopting RBM, but many still hesitate to jump on the bandwagon....read more
A common issue regarding “faltering” studies – studies that are not satisfying their time, cost, and quality parameters – is poor recruitment. Recruitment issues can delay deadlines and jeopardize the drug’s ultimate approval, if left unresolved. These delays are a...read more